Αναζήτηση
Αποτελέσματα 1-6 από 6
The Catabolic Role of Toll-Like Receptor 2 (TLR-2) Mediated by the NF-kappa B Pathway in Septic Arthritis
(2011)
Toll-like receptors (TLRs) are involved in mediating cell activation on stimulation with microbial components. Our objective was to investigate the role of 'PLR-2 mediated by the NF-kappa B pathway in septic arthritic ...
Involvement of SOX-9 and FGF-23 in RUNX-2 regulation in osteoarthritic chondrocytes
(2009)
Chondrocytes' hypertrophy includes metabolic changes, matrix remodelling, proliferation and apoptosis, characteristics associated with the progression of osteoarthritis. We investigated a possible association among ...
Bone morphogenetic protein-2-induced Wnt/beta-catenin signaling pathway activation through enhanced low-density-lipoprotein receptor-related protein 5 catabolic activity contributes to hypertrophy in osteoarthritic chondrocytes
(2012)
Introduction: Events normally taking place in the terminal chondrocyte differentiation in the growth plate are also observed during osteoarthritis (OA) development, suggesting that molecules, such as Wnts and bone morphogenetic ...
MicroRNA-33a regulates cholesterol synthesis and cholesterol efflux-related genes in osteoarthritic chondrocytes
(2015)
Introduction: Several studies have shown that osteoarthritis (OA) is strongly associated with metabolism-related disorders, highlighting OA as the fifth component of the metabolic syndrome (MetS). On the basis of our ...
Central Role of SREBP-2 in the Pathogenesis of Osteoarthritis
(2012)
Background: Recent studies have implied that osteoarthritis (OA) is a metabolic disease linked to deregulation of genes involved in lipid metabolism and cholesterol efflux. Sterol Regulatory Element Binding Proteins (SREBPs) ...
Migfilin's elimination from osteoarthritic chondrocytes further promotes the osteoarthritic phenotype via beta-catenin upregulation
(2013)
Osteoarthritis (OA) is a debilitating disease of the joints characterized by cartilage degradation but to date there is no available pharmacological treatment to inhibit disease progression neither is there any available ...